AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7075649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg retard
Number of subjects: 52
Study 31370840 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice case management in the intervention group
Number of subjects: 736
Study 31370840 — intervention group
Group type: COMPARATOR
Intervention: Routine care in the control group
Number of subjects: 736
Study 28427403 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (200 ml, 2 h before anesthesia) without ω-3 PUFA (CHO, n=14)
Number of subjects: 57
Study 28427403 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (CHO + W3, n=15)
Number of subjects: 57
Study 28427403 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (W3, n=14)
Number of subjects: 57
Study 28427403 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml, 2 h before anesthesia) without ω-3 PUFA (controls, n=14)
Number of subjects: 57
Study 25249468 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education from disease management nurses for 12 months, followed by 12 months of follow-up.
Number of subjects: 31
Study 25249468 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 24 months (control group).
Number of subjects: 31
Study 23391214 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management by a nurse combined with group support meetings based on the Stanford Chronic Disease Self‐Management Program
Number of subjects: 0
Study 23391214 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group (six months)
Number of subjects: 0
Study 21702705 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Opportunities Programme (EOP)
Number of subjects: 200
Study 21702705 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 200
Study 18063411 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment
Number of subjects: 15
Study 18063411 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 16829341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary change and smoking cessation advice
Number of subjects: 1232
Study 14669031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection of ox-LDL in temporal arteries with biopsy proven temporal arteritis (n=11)
Number of subjects: 23
Study 14669031 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=12)
Number of subjects: 23
Study 10963464 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal containing 200 microg of folic acid per serving
Number of subjects: 79
Study 10963464 — intervention group
Group type: COMPARATOR
Intervention: Breakfast cereal containing < 10 microg of folic acid per serving (placebo)
Number of subjects: 79
Study 8923021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 8923021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0
Study 8923021 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 2003044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 0
Study 2003044 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 6345167 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 757
Study 30861160 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg FDA-approved nasal spray
Number of subjects: 0
Study 30861160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg FDA-approved autoinjector
Number of subjects: 0
Study 30861160 — intervention group
Group type: COMPARATOR
Intervention: Improvised nasal naloxone device (INND) administered twice (2 mg each, separated by 2 minutes)
Number of subjects: 0
Study 29928996 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Number of subjects: 2160
Study 29928996 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (Collective Empowerment Education)
Number of subjects: 2160
Study 29928996 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT+CEE (Combination of ACT and CEE)
Number of subjects: 2160
Study 29928996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2160
Study 27807084 — intervention group
Group type: COMPARATOR
Intervention: Community-based intervention to improve growth among children under 2 years of age.
Number of subjects: 0
Study 24909469 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil alone (Group A)
Number of subjects: 40
Study 24909469 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium (Group B)
Number of subjects: 40
Study 22381072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change program (advice on lifestyle and treatment)
Number of subjects: 436
Study 22381072 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 436
Study 18722112 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) followed by breast conservation surgery with axillary dissection and radiation
Number of subjects: 0
Study 18722112 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 0
Study 17204566 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (1 g/day)
Number of subjects: 307
Study 17204566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 16360356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 334
Study 12062149 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects described as having conceptual properties typical of artifacts; children extended novel labels based on shape alone
Number of subjects: 0
Study 12062149 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects described as having conceptual properties typical of animate kinds; children extended novel labels based on shape and texture
Number of subjects: 0
Study 12062149 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient perceptual cue (object with eyes labeled in a story context); children extended the label based on shape alone
Number of subjects: 0
Study 9474617 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin (target INR 2.5-3.0) for 22 ± 9 weeks
Number of subjects: 26
Study 9474617 — intervention group
Group type: EXPERIMENTAL
Intervention: Winstrol (6 mg per day) for 16 ± 9 weeks
Number of subjects: 26
Study 7640234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1546
Study 7640234 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 1546
Study 2191444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 112
Study 2191444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 2191444 — intervention group
Group type: COMPARATOR
Intervention: Placebo with antibiotic therapy
Number of subjects: 112
Study 2191444 — intervention group
Group type: COMPARATOR
Intervention: Placebo with adrenal corticosteroid therapy
Number of subjects: 112
Study 2191444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (colonized by Candida sp)
Number of subjects: 112
Study 205020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic adenine arabinoside (Ara-A) at a dose of 5 mg/kg/day administered intravenously on an intermittent schedule
Number of subjects: 40
Study 205020 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 40
Study 205020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic adenine arabinoside (Ara-A)
Number of subjects: 40
Study 30634878 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mirroring System (FMS)
Number of subjects: 36
Study 30634878 — intervention group
Group type: COMPARATOR
Intervention: Conventional mirror book (MB) therapy
Number of subjects: 36
Study 30680983 — intervention group
Group type: EXPERIMENTAL
Intervention: sFLT-1/PlGF ratio in preterm delivery group
Number of subjects: 35
Study 30680983 — intervention group
Group type: EXPERIMENTAL
Intervention: sFLT-1/PlGF ratio in preterm delivery PE group
Number of subjects: 35
Study 30680983 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean delivery in PE group
Number of subjects: 35
Study 30680983 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications of preeclampsia in PE group
Number of subjects: 35
Study 30680983 — intervention group
Group type: EXPERIMENTAL
Intervention: sFLT-1/PlGF ratio
Number of subjects: 35
Study 28111966 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 months
Number of subjects: 131
Study 28111966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 28111966 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with albuminuria (n=34)
Number of subjects: 131
Study 25714582 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (EF) supplemented with bovine MFGM
Number of subjects: 160
Study 25714582 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 160
Study 22791467 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring sensor (CGMS)
Number of subjects: 188
Study 22791467 — intervention group
Group type: COMPARATOR
Intervention: Point of care glucose monitors
Number of subjects: 188
Study 21755716 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl* Plus
Number of subjects: 184
Study 21755716 — intervention group
Group type: COMPARATOR
Intervention: Vicryl*
Number of subjects: 184
Study 19785937 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC therapy
Number of subjects: 40
Study 19785937 — intervention group
Group type: COMPARATOR
Intervention: Standard medication
Number of subjects: 40
Study 19785937 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study 16681333 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component tobacco intervention (sports sponsorship, health promotion campaigns, training health professionals, school education about tobacco, policy on smoke-free public places)
Number of subjects: 920
Study 16681333 — intervention group
Group type: COMPARATOR
Intervention: Matched control community
Number of subjects: 920
Study 14652762 — intervention group
Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 23
Study 11404379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with MAGE peptides (group A)
Number of subjects: 26
Study 11404379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with MAGE peptides plus KLH (group B)
Number of subjects: 26
Study 9058626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid for 12 months
Number of subjects: 24
Study 9058626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid + azathioprine + prednisone
Number of subjects: 24
Study 9058626 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 24
Study 8147083 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-activating occupational therapy (study group)
Number of subjects: 22
Study 8147083 — intervention group
Group type: COMPARATOR
Intervention: Normal program of functional rehabilitation (control group)
Number of subjects: 22
Study 3524169 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 29206647 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intravenous sodium loading (hypertonic saline 5 mmol sodium/liter body water for 30 minutes)
Number of subjects: 12
Study 29206647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dietary sodium loading (more than 200 mmol/day for eight days)
Number of subjects: 12
Study 29206647 — intervention group
Group type: COMPARATOR
Intervention: Both sodium interventions (acute and chronic)
Number of subjects: 12
Study 29206647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dietary sodium loading
Number of subjects: 12
Study 29206647 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intravenous sodium loading
Number of subjects: 12
Study 27497806 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 103
Study 27497806 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 103
Study 24939310 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 1 min
Number of subjects: 25
Study 24939310 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 3 min
Number of subjects: 25
Study 24939310 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 5 min
Number of subjects: 25
Study 24939310 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 7 min
Number of subjects: 25
Study 24939310 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl (control group A)
Number of subjects: 25
Study 22105437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 1453
Study 22105437 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal disease (PD)
Number of subjects: 1453
Study 22105437 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of BV and PD
Number of subjects: 1453
Study 20480060 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswaks fluoridated in 0.1% NaF
Number of subjects: 10
Study 20480060 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswaks fluoridated in 0.5% NaF
Number of subjects: 10
Study 20480060 — intervention group
Group type: COMPARATOR
Intervention: Brushing with 1 g of F-containing dentifrice (0.32% NaF)
Number of subjects: 10
Study 18486203 — intervention group
Group type: EXPERIMENTAL
Intervention: H5‐KIDS program (home based intervention)
Number of subjects: 1306
Study 15966655 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive system (Clearfil Protect Bond)
Number of subjects: 35
Study 15966655 — intervention group
Group type: COMPARATOR
Intervention: One-step self-etching adhesive system (Xeno III)
Number of subjects: 35
Study 15966655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 35
Study 11815513 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 64
Study 11815513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10075321 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for 4 months
Number of subjects: 34
Study 10075321 — intervention group
Group type: COMPARATOR
Intervention: No physical training for 4 months (control)
Number of subjects: 34
Study 10075321 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 34
Study 8649135 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK with 20 minutes of CPB prior to cardioplegic arrest
Number of subjects: 20
Study 8649135 — intervention group
Group type: COMPARATOR
Intervention: Control group with no GIK and no CPB support
Number of subjects: 20
Study 2246313 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antibiotic bowel preparation
Number of subjects: 30
Study 2246313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic bowel preparation)
Number of subjects: 30
Study 6118716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-modified diet (diet B, 27% energy from fat, P/S 1.0, reduced cholesterol content)
Number of subjects: 12
Study 6118716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-modified diet supplemented with fruit, vegetable, and cereal fibre (diet C)
Number of subjects: 12
Study 6118716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet providing 40% energy from fat, P/S ratio 1.0 and supplemented by fibre (diet D)
Number of subjects: 12
Study 6118716 — intervention group
Group type: COMPARATOR
Intervention: Western reference diet (40% energy from fat, P/S ratio 0.27)
Number of subjects: 12
Study 6403171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Doppler ultrasound during fetal heart rate monitoring
Number of subjects: 150
Study 6403171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 150
Study 30499065 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-elicitation instrument (version identified as well accepted)
Number of subjects: 200
Study 30499065 — intervention group
Group type: COMPARATOR
Intervention: Four versions of the preference-elicitation instrument
Number of subjects: 200
Study 27863480 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered cognitive behavioral therapy intervention group
Number of subjects: 62
Study 27863480 — intervention group
Group type: COMPARATOR
Intervention: Standard information-only group (control)
Number of subjects: 62
Study 24262684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Bakri balloon immediately following placental delivery
Number of subjects: 52
Study 24262684 — intervention group
Group type: COMPARATOR
Intervention: Usual surgical/pharmacologic measures to achieve hemostasis
Number of subjects: 52
Study 22162534 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (2, 5, and 10 mg) administered once daily for 10 days
Number of subjects: 0
Study 22162534 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 (10 mg) administered once daily for 10 days
Number of subjects: 0
Study 20921870 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious attachment
Number of subjects: 110
Study 20921870 — intervention group
Group type: COMPARATOR
Intervention: Care coordinators' reports
Number of subjects: 110
Study 18386046 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM course in combination with case method learning sessions (CMLSs)
Number of subjects: 49
Study 18386046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 16212575 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis
Number of subjects: 96
Study 12030591 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy drink (402 kJ)
Number of subjects: 27
Study 12030591 — intervention group
Group type: COMPARATOR
Intervention: Low energy drink (1 kJ)
Number of subjects: 27
Study 10025428 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI pattern with hyperintense lateral rim and dorsolateral hypointense signal attenuation on T2-weighted images
Number of subjects: 90
Study 10025428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypointense changes in the putamen
Number of subjects: 90
Study 7723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Data base approach to assess relative efficacy of alternative therapies
Number of subjects: 0
Study 7723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconsideration of necessity for RCT
Number of subjects: 0
Study 7723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance program
Number of subjects: 0
Study 7723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording reasons for therapy selection
Number of subjects: 0
Study 2107581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro‐ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR)
Number of subjects: 18
Study 2107581 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (MD) plus hydrochlorothiazide (HCT)
Number of subjects: 18
Study 2107581 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance
Number of subjects: 18
Study 2107581 — intervention group
Group type: COMPARATOR
Intervention: Adverse effects
Number of subjects: 18
Study 2107581 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 18
Study 7410745 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 11
Study 7410745 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 11
Study 7410745 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 11
Study 7410745 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (Theophylline, Terbutaline, Prednisone)
Number of subjects: 11
Study 30782027 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Sitting (EX+SIT)
Number of subjects: 67
Study 30782027 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Breaks (EX+BR)
Number of subjects: 67
Study 30269276 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 leucovorin (LV)
Number of subjects: 80
Study 30269276 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/m2 leucovorin (LV)
Number of subjects: 80
Study 30269276 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/m2 leucovorin (LV)
Number of subjects: 80
Study 30269276 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/m2 leucovorin (LV) (untreated)
Number of subjects: 80
Study 26818098 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3 L
Number of subjects: 795
Study 26818098 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6D
Number of subjects: 795
Study 26818098 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐12
Number of subjects: 795
Study 26818098 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ
Number of subjects: 795
Study 23954038 — intervention group
Group type: EXPERIMENTAL
Intervention: PID‐C (personalized intervention for depressed patients with COPD)
Number of subjects: 138
Study 23954038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 23954038 — intervention group
Group type: EXPERIMENTAL
Intervention: PID‐C
Number of subjects: 138
Study 21923839 — intervention group
Group type: EXPERIMENTAL
Intervention: Any time users of prednisone
Number of subjects: 1051
Study 21923839 — intervention group
Group type: COMPARATOR
Intervention: Non-users of prednisone
Number of subjects: 1051
Study 21923839 — intervention group
Group type: EXPERIMENTAL
Intervention: Users of prednisone for 30 or more days
Number of subjects: 1051
Study 19679284 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 755
Study 19679284 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 755
Study 17635470 — intervention group
Group type: EXPERIMENTAL
Intervention: Malan radiological sinusitis typing (RST) system
Number of subjects: 10
Study 17635470 — intervention group
Group type: COMPARATOR
Intervention: Lund‐Mackay (LM) system
Number of subjects: 10
Study 15026873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stenting
Number of subjects: 50